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IMPORTANCE In Duchennemuscular dystrophy (DMD), the reading frame of an out-of-frame
DMD deletion can be repaired by antisense oligonucleotide (AO)–mediated exon skipping.
This creates a shorter dystrophin protein, similar to those expressed in themilder Becker
muscular dystrophy (BMD). The skipping of some exons may bemore efficacious than others.
Patients with exon 44 or 45 skippable deletions (AOs in clinical development) have a less
predictable phenotype than those skippable for exon 51, a group in advanced clinical trials. A
way to predict the potential of AOs is the study of patients with BMDwho have deletions that
naturally mimic those that would be achieved by exon skipping.
OBJECTIVE To quantify dystrophin messenger RNA (mRNA) and protein expression in
patients with DMD deletions treatable by, or mimicking, exon 44 or 45 skipping.
DESIGN, SETTING, AND PARTICIPANTS Retrospective study of nondystrophic controls (n = 2),
patients with DMD (n = 5), patients with intermediate muscular dystrophy (n = 3), and
patients with BMD (n = 13) at 4 university-based academic centers and pediatric hospitals.
Biochemical analysis of existing muscle biopsies was correlated with the severity of the
skeletal muscle phenotype.
MAIN OUTCOMES ANDMEASURES DystrophinmRNA and protein expression.
RESULTS Patients with DMDwho have out-of-frame deletions skippable for exon 44 or 45
had an elevated number of revertant and trace dystrophin expression (approximately 19% of
control, using quantitative immunohistochemistry) with 4 of 9 patients presenting with an
intermediate muscular dystrophy phenotype (3 patients) or a BMD-like phenotype (1
patient). Corresponding in-frame deletions presented with predominantly mild BMD
phenotypes and lower dystrophin levels (approximately 42% of control) than patients with
BMDmodeling exon 51 skipping (approximately 80% of control). All 12 patients with in-frame
deletions had a stable transcript compared with 2 of 9 patients with out-of-frame deletions
(who had intermediate muscular dystrophy and BMD phenotypes).
CONCLUSIONS AND RELEVANCE Exon 44 or 45 skipping will likely yield lower levels of
dystrophin than exon 51 skipping, although the resulting protein is functional enough to often
maintain a mild BMD phenotype. Dystrophin transcript stability is an important indicator of
dystrophin expression, and transcript instability in DMD compared with BMD should be
explored as a potential biomarker of response to AOs. This study is beneficial for the planning,
execution, and analysis of clinical trials for exon 44 and 45 skipping.
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D uchenne muscular dystrophy (DMD) is caused byframe-disruptingmutations in theDMDgene thatpre-vent the full translation of its protein product,
dystrophin.1,2 Duchenne muscular dystrophy is character-
ized by progressive muscle weakness and degeneration re-
sulting in loss of ambulation at approximately 13 years of age
in the steroid-treated population3 anddeath from respiratory
and/or cardiac failure in the thirdor fourthdecadeof lifewhen
supportedbynoninvasiveventilation.4-6 In-frame (IF) dystro-
phinmutations thatdonotdisrupt theopenreading frametypi-
cally cause a clinicallymilder disorder, Beckermuscular dys-
trophy (BMD).7,8 The IFmutations result in the translation of
an internally deleted dystrophin protein; variations in the
amount and functionality of these different dystrophin pro-
teins contribute to thevariablephenotypic spectrumofBMD.9
Dystrophin is a large sarcolemmal protein that forms part
of the dystrophin-associated protein complex.10,11 Dystro-
phin protects muscle fibers against the mechanical forces of
contraction and plays a role in signaling; the loss of dystro-
phin leads to secondary sarcolemmal protein deficiencies.
Antisense oligonucleotide (AO)–mediated exon skipping
aims to restore theDMD reading frame toallow theproduction
of an internally deleted dystrophin protein and, hopefully, a
functional benefit to patients with DMD who have out-of-
frame (OOF) deletions.12-14 The restoration of dystrophin and
membersofthedystrophin-associatedproteincomplexhasbeen
achieved following local and systemic injectionsofAOs target-
ing exon 51.15-19 Efforts are now focused on targeting other
exons12,20; however, the skipping of some exonsmay bemore
efficacious thanothers.Topredict thepotentialofvariousexon
skippingstrategies,westudiedpatientswithBMDwhohavede-
letions that naturally mimic those achieved by exon skipping.
Wepreviouslyquantifieddystrophin inpatientswithBMD
who have IF deletions that mimic skipping of exons 51, 45
through 55, and 53.21 While these results proved encouraging
for exon 51 and 53 skipping, several factors should be consid-
eredwhendeveloping and assessing the efficacy of strategies
for skipping exons44 and45,which are among themost com-
monDMD skippable exons. First, the percentage of revertant
and trace dystrophin expression in patients with deletions
flankingexon44 is significantlyhigher thanwithdeletionssur-
rounding exon 51.22 Second, OOF deletions around exons 44
and 45 result in a variety of clinical severities including inter-
mediate muscular dystrophy (IMD) and BMD.23-27
Herein, we characterize patients with IF and OOF DMD
deletions around exons 44 and 45 to enhance the planning,
execution, and analysis of clinical trials for exon 44 or 45
skipping.
Methods
Twenty-one patients (Table 1) were retrospectively selected
from4centers: (1)UniversityCollegeLondon, InstituteofChild
Health and Great Ormond Street Hospital, London, England;
(2) Institute of GeneticMedicine, Newcastle University, New-
castle, England; (3) Institute of Neurology, Catholic Univer-
sity School ofMedicine, Rome, Italy; and (4)University of Fer-
rara, Ferrara, Italy. Research ethics committee approval was
obtained from the London–West LondonGeneTherapyAdvi-
soryCommittee.Local researchanddevelopmentapprovalwas
also obtained from Great Ormond Street Hospital and the In-
stitute of Child Health.
Selection criteria included an IForOOFDMDdeletion rel-
evant to exon 44 or 45 skipping28 (confirmed bymultiplex li-
gation-dependent probe amplification) and the availability of
a muscle biopsy. A standardized questionnaire was distrib-
uted to obtain information on geneticmutation, age at onset,
age at biopsy, motor function abilities at the latest assess-
ment, and other comorbidities.
Patients with BMDwere classified as asymptomatic, hav-
ing mild BMD, or having severe BMD according to the age at
onset, relevant history, and overall motor function through-
out the disease course. Asymptomatic individuals had no de-
tectable muscle weakness and the only pathological feature
wasanelevatedserumcreatinekinase level.MildBMDwasde-
fined as havingmild proximalmuscleweakness but retaining
runningabilitybeyondadolescence. Individualswhoeither lost
running ability by the end of adolescence or never ran were
classified as having severe BMD.
Skeletal muscle biopsies (14 quadriceps, 4 deltoid, and 3
unknown) were previously obtained with written informed
consent. Nondystrophin controlmuscle biopsies (n = 2, para-
spinal and intercostal muscles) were obtained from the MRC
Centre for Neuromuscular Diseases Biobank, London (http:
//www.cnmd.ac.uk). Biochemical analysis of all samples was
performed in London to minimize variability.
Quantitative immunohistochemistry was performed as
previously described.21 A 2-tailed unpaired t testwas used for
statisticalanalysis, andstatistical significancewassetatP = .05.
Westernblottingwasperformedaspreviouslydescribed.21
Dystrophin intensity was normalized to α-actinin using Im-
ageLaboratory software (BioRad) and expressed as a percent-
age of control.
Total RNA was extracted, DNase treated, reverse tran-
scribed, and subjected to quantitative polymerase chain
reaction as previously described.29 Three dystrophin Taq-
Man assays (Applied Biosystems) were used with probes
spanning the junctions of exons 19 and 20, 53 and 54, and 73
and 74 (Table 2). Starting concentrations were calculated
using the LinRegPCR program.30,31 Data were normalized to
myotilin and presented relative to control. A 2-way analysis
of variance and Bonferroni posttest were used to determine
statistical significance.
Results
Westudied a total of 21 patients (Table 1). Of these, 9 hadOOF
deletions skippable by exon 44 or 45 (models 44 and 45 OOF)
and 12 had IF deletions mimicking the skipping of exon 45
(model 45 IF).
Clinical Characteristics
Four of 9 patients (44.4%) with OOF deletions had an IMD or
BMD phenotype. Patients 1 and 2 (both with IMD) were
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ambulant at ages 15 and 14 years, respectively, despite having
discontinued steroids. Patients 3 (with IMD) and6 (withBMD)
are still ambulant at ages 17 and 37 years, respectively. All 12
patients with IF deletions had a BMD phenotype. Their aver-
age age at study was 9 years (range, 3-33 years) and the aver-
age age at onset was 5 years (range, 1-9 years). Of the 12 pa-
tients with IF deletions and BMD, 1 was asymptomatic, 8 had
mild BMD, and 3 had severe BMD. Patient 14with asymptom-
aticBMDwasdiagnosed incidentallyatage3yearsandwasable
to run when last seen at the clinic at age 14 years. Patient 18
with severe BMD presented at age 9 years and by age 14 years
hecouldnot runandcouldonlywalk foramaximumof 10min-
utes. Patients 17 and 19 with severe BMD had ages at onset of
5 and 3 years, respectively; while both retaining ambulation
into their late teens, neither can run and patient 17 requires a
wheelchair for long distances.
Table 1. Summary of Clinical Features
Patient
No.
Exon
Deletion
Exon Skipping
Model Frame
Age at
Biopsy, y
Age at
Onset Phenotype Symptoms Motor Function
1 42-43 44 OOF 7 6 y IMD Unable to jump Walking indoors at age 15 y
2 42-43 44 OOF 9 3 y IMD Motor delay Walking indoors at age 14 y
3 45 44 OOF 8 Unknown IMD Toe walking Ambulant at age 17 y, not running,
difficulty climbing stairs
4 45 44 OOF 3 2 y DMD Frequent falls LOA at age 11 y
5 45 44 OOF 1 17 mo DMD Delayed walking, diagnosed by
incidental high serum
CK level
LOA at age 12 y
6 44 45 OOF 17 Teens BMD … Ambulant indoors at age 37 y
7 44 45 OOF 5 2 y DMD Difficulty walking LOA at age 11 y
8 44 45 OOF 4 2 y DMD Delayed walking LOA at age 11 y
9 46-47 45 OOF 5 4 y DMD Frequent falls, unable to jump LOA at age 11 y
10 45-47 45 IF 8 5 y BMD (mild) Walking and learning
difficulties
Ambulant at age 20 y,
difficulty climbing stairs
11 45-47 45 IF 16 8 y BMD (mild) Difficulty walking Ambulant at age 33 y,
difficulty climbing stairs
12 45-47 45 IF Unknown Unknown BMD (mild) … Ambulant at age 13 y
13 45-47 45 IF 7 6 y BMD (mild) Enlarged calves Ambulant at age 9 y,
swimming and sporty
14 45-47 45 IF 3 3 y BMD
(asymptomatic)
Incidental finding Able to run at age 14 y,
Gowers sign negative
15 45-48 45 IF 6 5 y BMD (mild) Difficulty walking Able to run at age 19 y, plays football
16 45-48 45 IF 33 8 y BMD (mild) Difficulty climbing stairs Ambulant at age 36 y
17 45-49 45 IF 7 5 y BMD (severe) Unable to jump,
calf hypertrophy
Ambulant at age 17 y, wheelchair for long
distances, struggles to rise from floor
18 45-49 45 IF 10 9 y BMD (severe) Calf hypertrophy,
motor difficulties
Ambulant for maximum of 10 min
at age 14 y, wheelchair for long distances
19 45-49 45 IF 3 3 y BMD (severe) Incidental finding,
severely autistic
Ambulant at age 14 y, unable to run
20 45-49 45 IF 5 5 y BMD (mild) Motor and learning difficulties,
behavioral problems
Ambulant at age 15 y, able to run,
plays football
21 45-49 45 IF 6 1-2 y BMD (mild) Difficulty rising from floor Ambulant at age 21 y
Abbreviations: BMD, Becker muscular dystrophy; CK, creatine kinase;
DMD, Duchennemuscular dystrophy; IF, in-frame; IMD, intermediate muscular
dystrophy; LOA, loss of ambulation; OOF, out-of-frame; ellipses, unreported.
Table 2. TaqMan Assay Sequences
Assay
Primer
Probe
Product
Length,
bp
Mean
PCR
EfficiencyaForward Reverse
Dystrophin 19 (Exon 19)
TCAGGCCCTGGTGGAACA
(Exon 20)
CTGAGGCTTGTTTGATGCTATCTG
TGGTGAATGAGGGTGTTAA 65 1.81
Dystrophin 53 (Exon 53)
GTCCCTATACAGTAGATGCAATCCAA
(Exon 54)
GCCACTGGCGGAGGTCTT
CCAAGCAGTTGGCC 75 1.80
Dystrophin 73 (Exon 73)
assay Hs01049401_m1b
(Exon 74)
assay Hs01049401_m1b
Assay Hs01049401_m1b 105 1.90
Myotilin (Exon 4)
assay Hs00199016m1b
(Exon 5)
assay Hs00199016m1b
Assay Hs00199016m1b 57 1.86
Abbreviations: bp, base pairs; PCR, polymerase chain reaction.
a Representative mean experimental efficiencies used to calculate starting
concentration, N0. All assays had efficiencies greater than 90%when
determined using the standard curvemethod on
unlimited samples.
bApplied Biosystems catalog assay; exact sequences are unavailable.
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Quantification of Dystrophin Protein
and Transcript Expression
Dystrophinprotein expressionwasquantifiedby immunohis-
tochemistryusingMANDYS106(exon43),MANEX50(exons49-
50), and Dys2 (last 17 C-terminal amino acids) antibodies.
Dystrophin levels in themodel 44OOF group had amean
(SD) of approximately 20% (18.3%) of control forMANDYS106,
approximately 25% (14.4%) for MANEX50, and approxi-
mately 16% (6.4%) forDys2 (Figure 1AandeFigure 1 in Supple-
ment). Patients in the model 45 OOF group had comparable
mean (SD) levels of approximately 18% (20.2%) of control for
MANDYS106, approximately 21% (24.3%) for MANEX50, and
approximately 22% (26.0%) for Dys2. Higher levels of dystro-
phinexpressionwereobserved in themodel45 IFgroup,which
had a mean (SD) of approximately 44% (6.8%) of control for
MANDYS106,approximately41%(8.8%) forMANEX50,andap-
proximately 43% (9.2%) for Dys2 (Figure 1A). Patients 1 and 2
lack the MANDYS106 epitope and patients 17 through 21 lack
theMANEX50epitope; thesedatapointswereexcludedas they
do not represent dystrophin content.
Notable variability was observed between patients with
OOF and IF deletions (Figure 1A and eFigure 1 in Supple-
ment). Patients 3 (with IMD) and 6 (with BMD) had relatively
high dystrophin levels (approximately 41.0% and 48.4%, re-
spectively, forMANDYS106),while patients 4 and 5withDMD
had low levels of dystrophin expression (approximately 9.1%
and8.8%, respectively, forMANDYS106).Meandystrophin lev-
els for themodel 45 IF groupwere significantly higher than at
least 1 of the OOF groups with all 3 antibodies (Figure 1A).
We compared the mean level of dystrophin protein ex-
pression in the IF andOOFgroupsvspatientswith IF andOOF
deletions from our previous study on patients with deletions
relevant to exon 51 skipping (Figure 1A).21 The level of dystro-
phin in OOFmodels 44 and 45 was higher than with OOF de-
letionsskippable forexon51.Conversely, themodel45 IFgroup
had a lower dystrophin level (mean [SD], 44% [6.8%] for
MANDYS106and43%[9.2%] forDys2) than thatpreviously re-
ported for the IFmodel 51 group (mean [SD], 84% [15.8%] for
MANDYS106 and 79% [17.1%] for Dys2).
Wenext quantifieddystrophinprotein expression in6pa-
tients (patient 7 with DMD and patients 12, 14, 15, 16, and 20
withBMD)byWesternblotting (Figure 1B).Nodystrophinwas
detected for patient 7withDMD,while the patientswithBMD
had amean (SD) dystrophin protein expression of 17% (7.5%)
of control. In our previous study on patients with BMDmim-
icking exon 51 skipping, Western blotting revealed a dystro-
phin level of approximately 65% of control21 (Figure 1B), con-
firming thatdystrophinproteinexpression in this currentBMD
cohort is relatively low.
It has been suggested that it is the stability rather than the
amountof theDMD transcript thatdetermines the level ofdys-
trophinprotein and that there is a 5′ to 3′ imbalance in the sta-
bility of the dystrophin transcript.32-35 We quantified dystro-
phinmessengerRNA (mRNA) and investigated, indirectly, the
stabilityof thedystrophintranscriptusingTaqManassaysspan-
ning exon junctions 19 and 20, 53 and 54, and 73 and 74
(Figure 1C and eFigure 2 in Supplement). The relative expres-
sion of dystrophinmRNAusing a TaqMan assay for the 5′ end
of the transcript was similar to control in all 21 patients and
the level of dystrophin mRNA does not correlate to the level
of dystrophin protein (Figure 1, and eFigure 1 and eFigure 2 in
Supplement). We observed a decrease in transcript levels in
somepatientswith the exon junction 53 and 54 assay (ie, 3′ to
the deletion breakpoint) that was more pronounced in pa-
tientswithOOFdeletions.Model45OOFandmodel45 IFgroup
meanswerestatisticallydifferentwith theexon junction73and
74 probe (P = .03) (Figure 1C), with 7 of 9 patients in the OOF
group (patients 1, 2, 4, 5, 7, 8, and9) showing a clearDMD tran-
script instability (eFigure 2 in Supplement). Interestingly, all
thesepatientshavebeendiagnosedashavingDMDor IMDand
low dystrophin levels compared with patients with a more
stable dystrophin transcript. Patients 3 and 6 with IMD were
theonly2patientswithOOFdeletions that retainedahigh level
ofDMDmRNAexpressionwith theexon junction73 and74as-
say (mean [SD], approximately 1.35 [0.30] and 0.83 [0.08], re-
spectively); thesepatientsalsohad thehighestdystrophinpro-
tein levels among the OOF cohort (mean [SD], approximately
40.6% [10.66%] and 48.4% [20.07%], respectively, with
MANDYS106). Similarly, all patientswithBMDwhohave IFde-
letions retained a high level of DMD mRNA with all 3 assays
(mean [SD], approximately 1.09 [0.27] for the exon junction 19
and 20 assay, approximately 1.16 [0.58] for the exon junction
53and54assay,andapproximately1.10 [0.24] for theexon junc-
tion 73 and 74 assay) (Figure 1C).
Quantification of Dystrophin-Associated Protein Expression
To assess the functional properties of the different dystro-
phin proteins expressed in our cohort, we quantified the ex-
pression of β-dystroglycan, neuronal nitric oxide synthase
(nNOS), and utrophin by quantitative immunohistochemis-
try (Figure 2 and eFigure 3 in Supplement).
The mean (SD) β-dystroglycan levels in the OOF and IF
groupswere lower thancontrol andhighly comparable (model
44OOF: approximately 41% [8.9%] of control;model 45OOF:
approximately 42% [12.0%] of control; and model 45 IF: ap-
proximately 43% [9.9%] of control). These levels appear un-
related to the level of dystrophin protein expression (Figure 1
and eFigure 1 in Supplement). β-Dystroglycan levels in pa-
tients with IF deletions were lower than those with IF dele-
tionsmimickingexon51skipping (Figure2), reflectingthe lower
level of dystrophin observed in this study; conversely, the
β-dystroglycan levels in the OOF groups were higher than in
patients with OOF deletions mimicking exon 51 skipping
(Figure 2).21
All but 1 (patient 9) of the 21 patients have incomplete
nNOS-binding domains (encoded by exons 42-45); conse-
quently, thesepatientshavevirtually absent levelsofnNOSex-
pression,with patient 9 having the highest level of 8.8%. Sar-
colemmal nNOS protein expression was significantly lower
with the model 45 IF group compared with both OOF groups
(Figure 2).
There is limited information on the levels of the dystro-
phinhomologutrophin inBMDor towhat extentutrophinand
dystrophin are present together at the sarcolemma.36-38 The
2OOFmodels hadhighmean (SD) levels of sarcolemmal utro-
phin expression (model 44OOF: approximately 501% [94.7%]
Research Original Investigation DMDDeletions Pertinent to Exon 44 or 45 Skipping
E4 JAMANeurology Published online November 11, 2013 jamaneurology.com
Downloaded From: http://archneur.jamanetwork.com/ by a University College London User  on 11/14/2013
Copyright 2013 American Medical Association. All rights reserved.
of control; and model 45 OOF: approximately 438% [235.1%]
of control). The model 45 IF group had a significantly lower
and less variable mean (SD) level of approximately 280%
(63.5%)of control,whichwashigher than inpatientswithBMD
modeling exon 51 skipping (mean [SD], approximately 159%
[46.3%] of control) (P < .001) (Figure 2). We did not identify a
Figure 1. Comparative Analysis of Dystrophin Protein and Transcript Expression in PatientsWith In-Frame or Out-of-FrameDMDDeletions Around
Exons 44 and 45
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A, Transverse muscle sections were immunolabeled for β-spectrin,
MANDYS106, MANEX50, and Dys2. Protein expression was quantified relative
to control muscle in 40muscle fibers and normalized to β-spectrin expression.
Patients were grouped according to corresponding exon skippingmodels for
Duchennemuscular dystrophy: control, exon 44 or 45 skippable out-of-frame
(OOF) deletions (model 44 OOF andmodel 45 OOF), and in-frame (IF)
deletions mimicking exon 45 skipping (model 45 IF). Data are presented as
mean (SD) of the difference between sample means. Dotted lines indicate the
mean dystrophin protein expression level from patients with Becker muscular
dystrophy who have IF (blue lines) and OOF (gray lines) deletions modeling
exon 51 skipping quantified in our previous study.21 B, Western blotting analysis
of patients 7, 12, 14, 15, 16, and 20. Data are normalized to α-actinin and
presented as themean (SD) percentage of control. Dotted line indicates the
mean dystrophin protein expression level from patients with Becker muscular
dystrophy who have IF deletions modelling exon 51 skipping quantified in our
previous study.21 C, The DMDmessenger RNA transcript levels were quantified
using 3 separate TaqMan assays (Applied Biosystems) targeting exon
boundaries 19 and 20, 53 and 54, and 73 and 74. Themean polymerase chain
reaction efficiency per amplicon (Table 2) and themean threshold cycle (Ct)
value per sample were used to calculate the starting concentration (N0) using
the equationN0 = Nt/ECtwhere Nt is the fluorescence threshold and E is the
efficiency. Data were normalized tomyotilin, and dystrophin transcript
expression is presented as mean (SD) relative to control.
aP = .002.
bP = .001.
cP = .03.
dP < .001.
eP = .02.
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relationship between the levels of dystrophin and utrophin.
Patient 3 with IMD had among the highest sarcolemmal dys-
trophin and utrophin levels (mean [SD], approximately 41%
[10.7%] with MANDYS106 and 540% [202.3%] of control, re-
spectively); however, a similar level of dystrophin expression
in patient 6with IMD (mean [SD], approximately 48% [20.1%]
of control) was accompanied by a lower level of sarcolemmal
utrophin (mean [SD], approximately 182% [100.5%] of con-
trol) (Figure 1 and eFigure 3 in Supplement).
We found no obvious difference in themean or spread of
dystrophin or dystrophin-associated protein expression be-
tweenpatientswithBMDofdifferent severities (eFigure 1 and
eFigure 3 in Supplement). We previously demonstrated that
the levels of dystrophin and somedystrophin-associatedpro-
teinsare correlatedwithclinical severity inaBMDcohortmim-
icking exon 51 skipping.21 Herein, we found no clear correla-
tion between dystrophin, β-dystroglycan, nNOS, or utrophin
proteinexpressionandclinical severity for themodel45group.
Asymptomatic patients, thosewithmildBMD, and thosewith
severe BMD have comparable dystrophin and dystrophin-
associated protein levels (Figure 3).
Discussion
Wehavequantitatively assessed the levels of dystrophin tran-
script and protein in a cohort of 21 patients with IF and OOF
deletions around exons 44 and 45. We compared these data
with our previous study21 to provide the most comprehen-
sive characterization of patients with BMD mimicking exon
skipping todate.Ourdata provide a robust baseline for the as-
sessment of dystrophin transcript and protein levels in boys
with DMD recruited into future clinical trials.
Patients in the model 44/45 OOF group had higher levels
of dystrophin protein than thosemodeling exon 51 or 53 skip-
ping.We attribute this to a higher level of revertant and trace
dystrophin expression in patients in the model 44/45 OOF
group.22,39Exon44skips spontaneouslywhensurroundingex-
ons are deleted40; patientswith these “leaky”mutations pre-
sentwithunpredictablephenotypes,whichhighlights the limi-
tation of an exclusively genetic diagnosis and the value of
accuratemuscle pathology. Indeed, 4 of 9 patients in ourOOF
cohort had IMD or BMD phenotypes instead of the expected
DMDphenotype.This is in stark contrast toOOFdeletions fur-
ther 3′ aroundexon51,whichpredictably present asDMD.21,41
Although in vitro data suggest that patients with leakymuta-
tions might be ideal candidates for exon skipping,39 the con-
sequences of the higher background levels of dystrophin and
the lower level of dystrophinprotein restoration that couldbe
achievedbyexon skipping in thesepatients areunknown.The
efficacy and efficiency of exon 44 and45AOswill thus be dif-
ficult to measure without pretreatment biopsies and sensi-
tive quantitativemethods. Phase I and II clinical trials of exon
44 and 45 AOs are under way (ClinicalTrials.gov identifiers
NCT01037309 andNCT01826474, respectively); in light of the
discusseddata, patientswithdifferent treatment responses in
these trials are likely. The higher level of dystrophin expres-
sion in patients eligible for exon 44 or 45 trials may influence
their immunity todystrophin.42 Immunity to self- andnonself-
dystrophinepitopes requires further investigationand should
be assessed in future DMD clinical trials.
In our study, recruitment may be biased toward patients
with severe BMD as many patients with asymptomatic BMD
pass undiagnosed. On this note, we could not recruit any pa-
tientswithBMDwhohavedeletionsmimicking exon44 skip-
ping; thus, our cohort cannot represent the full spectrum of
deletions in this area, some of which have never been re-
ported.Nevertheless, allpatientswith IFdeletions in this study
had dystrophin protein levels approximately 40% of control
and 9 of 12 patients hadmild BMD orwere asymptomatic. Al-
though our sample size is too small for meaningful analysis,
weconsideredourpreviouscohortof IFdeletionsaroundexon
Figure 2. Comparative Immunohistochemical Analysis of Dystrophin-Associated Protein Expression in PatientsWith In-Frame or Out-of-Frame
DMDDeletions Around Exons 44 and 45
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Transverse muscle sections were immunolabeled for β-spectrin, β-dystroglycan,
neuronal nitric oxide synthase (nNOS), and utrophin. Expression was quantified
relative to control muscle in 40muscle fibers and normalized to β-spectrin
expression. Patients were grouped according to corresponding exon skipping
models for Duchennemuscular dystrophy: control, exon 44 or 45 skippable
out-of-frame (OOF) deletions (model 44 OOF andmodel 45 OOF), and in-frame
(IF) deletions mimicking exon 45 skipping (model 45 IF). Data are presented as
mean (SD) of the difference between sample means. Dotted lines indicate the
mean dystrophin-associated protein expression level from patients with Becker
muscular dystrophy who have IF (blue lines) and OOF (gray lines) deletions
modeling exon 51 skipping.21
aP = .01.
bP < .001.
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51 less severe (and the dystrophin proteinmore stable and/or
functional) as only 1 of 17 patients had severe BMD,while 4 of
17 were asymptomatic.21
While a number of disease modifiers have been identi-
fied forDMD,43,44 no information is available onwhether they
contribute to BMD variability. Variability in BMD is likely af-
fected by the structure and stability of dystrophin. Our 12 pa-
tients with BMD maintain an intact hinge 3, which results in
more variable BMD phenotypes.45 The phasing of helical re-
peats in patientswith deletions in exons 45 to 47 and 45 to 49
is disrupted46; in our study, there are patients with asymp-
tomatic, mild, and severe BMDwith out-of-phase repeats.
Weobservednoclear correlationbetween the level of dys-
trophin transcript or protein expressionwith clinical severity
in patientswith IF deletionsmodeling exon 45 skipping. This
is in concordance with recently presented protein data on 13
patients with BMDwho have a deletion of exons 45 to 47.47
Antisenseoligonucleotide–mediatedexonskippingrelieson
theavailabilityof thedystrophintranscript.Our findingthatpa-
tientswith IFandOOFdeletionshave5′DMD transcriptexpres-
sionlevelscomparabletocontrol issupportedbystudiessuggest-
ing that transcript stability rather thanamount is important for
high levelsofdystrophinproteinexpression.35,48Weshowthat
all 12patientswith IFdeletionshadastable transcript,while all
patientswithanOOFdeletion(accompaniedbyalowlevelofdys-
trophinexpression)hadanunstabledystrophin transcript.This
is supported by another study that showed a 5′ to 3′ increase in
thresholdcyclevalues inpatientswithDMDwhohaveOOFde-
letionsandpointmutations.49Taken together, thesedatahigh-
light theneed for careful considerationof the locationof prim-
ersandprobeswhenquantifyingdystrophinmRNAandsuggest
that transcript stability correlateswithproteinproductionbet-
ter thanoverall transcript levels.Whetherexonskippingrestores
the stability of thedystrophin transcript invivoandhowexist-
Figure 3. Correlation of Dystrophin and Dystrophin-Associated Protein ExpressionWith Clinical Severity
in PatientsWith In-FrameDMDDeletions Around Exons 44 and 45
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ingpatient transcript instabilities (whichmayvaryaccording to
theOOFmutation) affect theoutcomeofexonskipping remain
to be determined. The assessment of DMD transcript stability
couldbeexploredasamarkerofresponsetotherapy.Recentdata
showthat the transcript imbalance ismorepronounced inmdx
miceharboringanonsensemutationvswildtype.35Thus,astrat-
egytorestoreandmaintainDMDtranscriptstabilitymayimprove
the efficiency of AO-mediated exon skipping.
In summary, our data suggest that, as with exon 51,
AO-mediated exon skipping of exon 44 or 45 may prove
beneficial to patients with DMD, as patients with IF muta-
tions in this region had a predominantly mild BMD pheno-
type. However, we highlight that the skipping of different
exons will likely yield different levels of dystrophin protein
restoration as well as dystrophin proteins that differ in their
stability and functionality.
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